Physician profile
Craig R Greben
NPI 1295805646
$455,538.05
in general payments reported to CMS, 2019-2025
9 companies · $68K in 2025
The $68K reported for 2025 was more than what 98% of Vascular & Interventional Radiology providers received nationally (typical 2025 total: $537).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61K · 2020: $62K · 2021: $72K · 2022: $62K · 2023: $69K · 2024: $62K · 2025: $68K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $198K · Food and Beverage: $310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $198,168.32 |
| Food and Beverage | $310.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $279,248.23 | 2020-2025 | Arrow, Trapliner |
| Vascular Solutions, INC. | $173,611.86 | 2019-2021 | |
| Dova Pharmaceuticals | $2,353.34 | 2019 | |
| Medtronic Vascular, INC. | $143.88 | 2020 | |
| Boston Scientific Corporation | $104.08 | 2021 | |
| Siemens Medical Solutions USA, INC. | $24.09 | 2024 | |
| Cardiva Medical, INC. | $19.41 | 2023 | Cardiva Vascade 6/7f Vcs |
| Ethicon US, LLC | $17.67 | 2022 | |
| Cardinal Health 200 LLC | $15.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Greben listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.